SLC5A2 and urinary tract infection: Five of the nine studies reported various adverse events associated with SGLT2 inhibitor use, including DKA, sepsis, urinary tract infection, genital infection, arrhythmia, hypoglycemia, amputation, and fournier’s gangrene.